FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change.

Andreas TraschützZofia FleszarHolger Hengel Thomas KlockgetherFriedrich ErdlenbruchBjörn H FalkenburgerThomas KlopstockÖzgür Öztop-ÇakmakJosé Luiz PedrosoFilippo M SantorelliLudger Schölsnull nullMatthis Synofzik

Published in: Movement disorders : official journal of the Movement Disorder Society (2024)

FARS-ADL reflects both disease severity and patient-meaningful impairment across genetic ataxias, with sensitivity to change in trial-relevant timescales in patients perceiving change. It thus presents a promising patient-focused outcome for upcoming ataxia trials. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

case report
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
randomized controlled trial
study protocol
prognostic factors
genome wide
phase iii
patient reported outcomes
phase ii